Archive for February 12th, 2013
by Mike Arnold
Belonging to the category of drugs known as GH secretagogues, Ipamorelin’s primary function is to stimulate the release growth hormone from the pituitary gland. Its fairly recent entrance into the marketplace has earned it the distinction of being a 3rd generation GHRP, noted for exhibiting several unique characteristics which differentiate it from the other drugs in its class. Its exclusive ability to maintain a high level of selectivity is its most promising attribute, as it is the only GHRP capable of achieving substantial elevations in growth hormone without a concomitant rise in prolactin or cortisol. This unique feature has caught the eye of pharmaceutical companies, making it a more likely contender for human clinical trials in the future. The high degree of selectivity demonstrated by Ipamorelin is in stark contrast to similar compounds, such as Hexarelin, GHRP-2, and GHRP-6, for example.
Read the rest of this entry »